# TECHNOLOGY OFFER

Institut de Recerca Sant Pau

## CAR-T Therapy

Advanced Therapy Medicinal Product for Hodgkin Lymphoma (HL) with high antitumor efficacy

## CLINICAL NEED

**Classical HL is a rare malignancy** that affects the lymphatic system, a part of the body's immune system, the natural defense against infection and disease.

The standard of care available is chemotherapy. Although HL is highly curable, **prognosis is worse in patients with advanced disease, with 30-40% relapse after initial treatment** or immediate treatment failure. Patients, who are not cured with front-line or second-line therapy have an estimated median survival of less than 3 years.

**Effective targeted therapies are needed** for refractory/relapsed patients.

## ASSET - INNOVATIVE ASPECTS

A **4th generation** Chimeric Antigen Receptor T cell (**CAR-T**) with **improved in vivo anti-tumor activity in a stress xenograft model of HL.** This novel therapy holds the potential to effectively treat HL relapsed patients.

## MARKET SITUATION

The HL treatment market is projected to grow significantly, with a **CAGR of 8.3% (2024-2030)**. This growth is attributed to **increasing diagnoses, advancements in diagnostic technology, and the development of new, more effective therapies**. The market is expected to reach $15.70 billion by the end of 2030.

## STAGE OF DEVELOPMENT




**The asset is at a preclinical stage of development, finishing preclinical studies leading to First-In-Human trials.** So far, relevant *in vitro* and *in vivo* has been generated. The asset showed an increased cytokine secretion after tumor encounter and a higher cytotoxic activity. Furthermore, an improved anti-tumor activity was showed in a stress xenograft model of HL, as compared with 2nd and 3rd generation CAR-Ts .

## TEAM

A **multidisciplinary team** lead by Dr Javier Briones (Director of Clinical Hematology at Hospital Santa Creu i Sant Pau- HSCSP), and further supported by Dr. Laura Escriba (Expert ATMP prduccion) and Dr. Ana Carolina Caballero (Hematologist at HSCSP).

**Dr Javier Briones**

**Dra Laura Escribà**

**Dra Ana Carolina**

**#Advanced Therapies #CART #Hodgkin Lymphoma #Improved Efficacy #Personalised Medicine**

## INTELLECTUAL PROPERTY

**European priority patent (EP24382133) and PCT (PCT/EP2025/053474)**
**Priority date:** 09/02/2024

CAR-T AND MODIFIED CD200R COMBINATION

The present disclosure relates to a combination of a CAR that targets an antigen highly expressed in cancers (i.e., CD30) which also typically express CD200, such as Hodgkin lymphoma, with a modified CD200R that has been found useful in the treatment of such cancers. The present disclosure further relates to polynucleic acids, vectors, immune cells, pharmaceutical compositions encoding or comprising said combination, the same for use in the treatment of cancer and methods of preparation of said immune cells.

Institut de Recerca Sant Pau
Carrer de Sant Quintí, 77
08041 Barcelona · www.recercasantpau.cat

Technology Transfer Office
innovacio@santpau.cat